Home

news001

Proximagen Signs Deal With Upsher-Smith

Proximagen Neuroscience plc, a biotechnology company focused on diseases of the central nervous system, announces that it has signed a development, license and sub-license agreement with Upsher-Smith Laboratories Inc. in relation to tonabersat, a drug compound recently acquired by Proximagen through its acquisition of Minster Pharmaceuticals plc.

Under the terms of the agreement, Upsher-Smith will undertake the clinical development, regulatory filing, and commercialization of tonabersat for epilepsy in the USA, Canada, and Mexico and Proximagen will be entitled to royalty-free use of Upsher-Smith’s arising clinical data when developing tonabersat for Europe, a market to which Proximagen is retaining full rights. Upsher-Smith will also be making an upfront payment to Proximagen and any royalties and milestone receipts arising from sub-licensing tonabersat in territories excluding North America and Europe will be shared equally between Proximagen and Upsher-Smith.

The agreement also includes the grant of a sub-license of certain patents and know-how which were originally licensed to Minster by SmithKline Beecham plc (GSK). GSK has been made aware of the partnering discussions with Upsher-Smith and their support has enabled the agreement with Upsher-Smith. The signing follows the announcement by Proximagen on March 10 that tonabersat had achieved positive efficacy results in National Institute of Health non-clinical epilepsy studies.

Source: Proximagen Neuroscience plc

News & Events

  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>